Aller au contenu principal

Case details

Case Number: UPC_APP_15433/2023

  • Patent number:
    EP1537859 - Azithromycin dosage forms with reduced side effects,
    EP1963302 - POLYMORPHS OF A C-MET/HGFR INHIBITOR,
    EP1730119 - IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS,
    EP4074702 - CRYSTALLINE FORMS OF 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE SUITABLE FOR THE TREATMENT OF ABNORMAL CELL GROWTH IN MAMMALS,
    EP1959955 - METHOD OF TREATING ABNORMAL CELL GROWTH,
    EP1865986 - ANTI-CTLA-4 ANTIBODY COMPOSITIONS,
    EP2134702 - CRYSTALLINE FORMS OF 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE SUITABLE FOR THE TREATMENT OF ABNORMAL CELL GROWTH IN MAMMALS,
    EP2620450 - Anti-CTLA-4 antibody compositions,
    EP3252047 - CRYSTALLINE FORMS OF 6-[2-(METHYLCARBAMOYL)PHENYLSULFANYL]-3-E-[2-(PYRIDIN-2-YL)ETHENYL]INDAZOLE SUITABLE FOR THE TREATMENT OF ABNORMAL CELL GROWTH IN MAMMALS

  • Proceeding type: Application

  • Action/Application: Dérogation

  • Applicants:
    Pfizer Represented by Delphine Greenwald

  • Court Division: appealInstance - seat - Luxembourg

  • Date of Formal receipt: 2023-04-04 11:31:28